FDA Approves Novartis’ Promacta to Treat Paediatric Patients
Novartis has received approval from the FDA for Promacta to treat children aged six years and older with chronic immune thrombocytopenia (ITP). ITP is a rare blood disorder that affects as many as five in 100,000 children every year and is characterised by a low platelet count. The drug has been approved for children with